JSR Corporation (Headquarter: Minato-ku, Tokyo; Representative Director, CEO, President Officer: Tetsuro Hori; hereinafter "JSR") announces that JSR Life Sciences, LLC, an indirectly wholly owned affiliate of JSR, has entered into an agreement to transfer all shares of its wholly owned subsidiary, Crown Bioscience international to Miramar Lifesciences Limited as a wholly owned subsidiary of Adicon Holdings Limited (HKEX: 9860.HK) (Headquarter: Hangzhou, China, Executive Director and Chief Executive Officer: Song Gao, hereinafter "Adicon"). The closing of this share transfer is expected to be consummated in the middle of the 2026 calendar year. By this share transfer, Crown Bioscience group of companies (Headquarter of the group: California, USA; CEO and COO of the group: John Gu; hereinafter "Crown") affiliated under Crown Bioscience International, excluding some entities, will be transferred to Adicon group.

Crown provide services as a contract research organization (CRO) to pharmaceutical and biotechnology companies worldwide. It offers a global preclinical and translational platform to advance drug discovery in oncology, cancer immunology. It provides high-quality, scalable in vivo, in vitro, and ex vivo preclinical models, collaborating with clients to quantify the efficacy and pharmacologic properties of candidate drugs at the preclinical stage.

Crown's mission is to support its clients in improving human health. It achieves this by recruiting outstanding scientists, meeting the highest quality standards, and relentlessly pursuing innovation. It remains committed to advancing exceptional new drug candidates so patients can access the right treatment at the right time. https://crownbio.jp/about-us/our-company

Adicon operates over 30 independent medical testing laboratories across China. Centered on three core platforms—R&D, pharmaceutical clinical trials, and testing services—it manages specialized labs in clinical, pathological, reproductive genetics, genetic, and mass spectrometry testing. With over 200 patents and more than 4,000 test items, it serves approximately 19,000 customers. Under an advanced management system compliant with international standards, it provides highly reliable results guided by its quality policy of "Science, Precision, Efficiency, Satisfaction." Twenty-five laboratories nationwide hold ISO 15189 accreditation (Hangzhou: 320 items), and advance testing sophistication and service quality through global collaboration. https://www.adicon.com.cn/adicon/about/

This share transfer enables JSR to concentrate resources on high-impact areas that will deliver maximum value to partners and customers going forward. We anticipate that Crown's innovative technologies will continue to evolve in Adicon group, enabling the faster and more reliable delivery of life-saving therapeutics.

JPMorgan Securities Japan Co., Ltd. (“J.P. Morgan”) is serving as exclusive financial advisor to JSR Corporation.